Palantir's AIPCon 10, Ramp Hits $44B, 60 Minutes Eyes Rogan | Diet TBPN

TL;DR

• 1

  Ramp's new round is about momentum, not just valuation: The hosts say Ramp's $750 million fundraise at a $44 billion valuation stands out because, in Eric Glyman's words, the company is growing this fast while being 120 times larger than the last time it had similar growth.

• 2

  AI labs and biotech companies are lining up behind DNA screening rules: Demis Hassabis, Sam Altman, Dario Amodei, Alex Wang, Twist Bioscience, Emerald Cloud Lab, and others signed a letter asking the US government to require nucleic acid synthesis screening, customer verification, and recordkeeping.

• 3

  The bio risk is no longer hypothetical because the blueprint is enough: They walk through how researchers synthesized polio from published sequence data in 2002 and reconstructed the 1918 Spanish flu in 2005, arguing that with AI and wider access to synthesis tools, dangerous sequence design gets easier.

• 4

  Voluntary safeguards still leave a glaring gap: About 80% of commercial gene synthesis is reportedly covered by the International Gene Synthesis Consortium, but the hosts stress that the number is self-reported and compliance is voluntary, joking that this is like saying 80% of nuclear weapons are safely stored.

• 5

  Biotech feels alive again after a long slump: They point to Isomorphic Labs, NewLimit, Retro, Altos Labs, Coefficient Bio, and projects tied to Jensen Huang and Larry Ellison as signs that capital and attention are swinging back toward biotech.

• 6

  Benchmark is changing with the market: The firm reportedly raised $2 billion across two new funds, including its first dedicated growth fund, which the hosts treat as the end of Benchmark's long run as a pure early-stage venture shop.